Undifferentiated Pleomorphic Sarcoma: Long-Term Follow-Up from a Large Institution

References

• O’Brien JE, Stout AP. Malignant fibrous xanthomas. Cancer. 1964;17:1445–1455. doi:10.1002/1097-0142(196411)17:11<1445:AID-CNCR2820171112>3.0.CO;2-G14223761
   PubMed Web of Science ®Google Scholar
• Daugaard S. Current soft-tissue sarcoma classifications. Eur J Cancer. 2004;40(4 ):543–548. doi:10.1016/j.ejca.2003.11.00914962721
   PubMed Web of Science ®Google Scholar
• Dei Tos AP. Classification of pleomorphic sarcomas: where are we now? Histopathology. 2006;48(1 ):51–62. doi:10.1111/his.2006.48.issue-116359537
   PubMed Web of Science ®Google Scholar
• Casali PG, Abecassis N, Aro HT, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4 ):iv51–iv67. doi:10.1093/annonc/mdy09629846498
   PubMedGoogle Scholar
• Fletcher C, Bridge J, Hogendoorn P, editors. WHO Classification of Tumors of Soft Tissue and Bone. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon (France): IARC Press; 2013.
   Google Scholar
• Nascimento AF, Raut CP. Diagnosis and management of pleomorphic sarcomas (so-called “MFH”) in adults. J Surg Oncol. 2008;97(4 ):330–339. doi:10.1002/(ISSN)1096-909818286476
   PubMed Web of Science ®Google Scholar
• Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer. 1978;41(6 ):2250–2266. doi:10.1002/1097-0142(197806)41:6<2250::AID-CNCR2820410626>3.0.CO;2-W207408
   PubMed Web of Science ®Google Scholar
• Fletcher CDM, Gustafson P, Rydholm A, Willén H, Åkerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol. 2001;19:3045–3050. doi:10.1200/JCO.2001.19.12.304511408500
   PubMed Web of Science ®Google Scholar
• Belal A, Kandil A, Allam A, et al. Malignant fibrous histiocytoma. Am J Clin Oncol. 2002;25(1 ):16–22. doi:10.1097/00000421-200202000-0000311823689
   PubMed Web of Science ®Google Scholar
• Casali PG. Adjuvant chemotherapy for soft tissue sarcoma. Am Soc Clin Oncol Educ Book. 2015;35(1 ):e629–e33.
   Google Scholar
• Dineen SP, Roland CL, Feig R, et al. Radiation-associated undifferentiated pleomorphic sarcoma is associated with worse clinical outcomes than sporadic lesions. Ann Surg Oncol. 2015;22(12 ):3913–3920. doi:10.1245/s10434-015-4453-z25743327
   PubMed Web of Science ®Google Scholar
• Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984;33:37–42. doi:10.1002/(ISSN)1097-02156693192
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6 ):1471–1474. doi:10.1245/s10434-010-0985-420180029
   PubMed Web of Science ®Google Scholar
• Roland CL, May CD, Watson KL, et al. Analysis of clinical and molecular factors impacting oncologic outcomes in undifferentiated pleomorphic sarcoma. Ann Surg Oncol. 2016;23(7 ):2220–2228. doi:10.1245/s10434-016-5115-526847678
   PubMed Web of Science ®Google Scholar
• Chen K-H, Chou T-M, Shieh S-J. Management of extremity malignant fibrous histiocytoma: a 10-year experience. Formosan J Surg. 2015;48(1 ):1–9. doi:10.1016/j.fjs.2014.06.003
   Google Scholar
• Peiper M, Zurakowski D, Knoefel WT, Izbicki JR. Malignant fibrous histiocytoma of the extremities and trunk: an institutional review. Surgery. 2004;135(1 ):59–66. doi:10.1016/S0039-6060(03)00325-814694301
   PubMed Web of Science ®Google Scholar
• Hsu HC, Huang EY, Wang CJ. Treatment results and prognostic factors in patients with malignant fibrous histiocytoma. Acta Oncol. 2004;43(6 ):530–535. doi:10.1080/0284186041001842115370609
   PubMed Web of Science ®Google Scholar
• Guo J, Cui Q, Liu C, et al. Clinical report on transarterial neoadjuvant chemotherapy of malignant fibrous histiocytoma in soft tissue. Clin Transl Oncol. 2013;15(5 ):370–375. doi:10.1007/s12094-012-0933-922975901
   PubMed Web of Science ®Google Scholar
• Zagars GK, Mullen JR, Polack A. malignant fibrous histiocytoma: outcome and prognostic factors following conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 1996;34(5 ):983–994. doi:10.1016/0360-3016(95)02262-78600111
   PubMed Web of Science ®Google Scholar
• Le Doussal V, Coindre J-M, Leroux A, et al. Prognostic factors for patients with localized primary malignant fibrous histiocytoma. Am Cancer Soc. 1996;77(9 ):1823–1830.
   Google Scholar
• Borucki RB, Neskey DM, Lentsch EJ. Malignant fibrous histiocytoma: database review suggests a favorable prognosis in the head and neck. Laryngoscope. 2018;128(4 ):885–888. doi:10.1002/lary.2690928988458
   PubMed Web of Science ®Google Scholar
• Sabesan T, Xuexi W, Yongfa Q, Pingzhang T, Ilankovan V. Malignant fibrous histiocytoma: outcome of tumours in the head and neck compared with those in the trunk and extremities. Br J Oral Maxillofac Surg. 2006;44(3 ):209–212. doi:10.1016/j.bjoms.2005.06.00616026908
   PubMed Web of Science ®Google Scholar
• Lehnhardt M, Daigeler A, Homann HH, et al. MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities – an analysis of 140 patients. Langenbecks Arch Surg. 2009;394(2 ):313–320. doi:10.1007/s00423-008-0368-518584203
   PubMed Web of Science ®Google Scholar
• Ozcelik M, Seker M, Eraslan E, et al. Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of anatolian society of medical oncology. Tumour Biol. 2016;37(4 ):5231–5237. doi:10.1007/s13277-015-4359-126553363
   PubMedGoogle Scholar
• Grimer RJ. Size matters for sarcomas! Ann R Coll Surg Engl. 2006;88(6 ):519–524. doi:10.1308/003588406X13065117059708
   PubMed Web of Science ®Google Scholar
• Kamat NV, Million L, Yao DH, et al. The outcome of patients with localized undifferentiated pleomorphic sarcoma of the lower extremity treated at Stanford University. Am J Clin Oncol. 2019;42(2 ):166–171. doi:10.1097/COC.000000000000049630557163
   PubMed Web of Science ®Google Scholar
• Winchester D, Lehman J, Tello T, et al. Undifferentiated pleomorphic sarcoma: factors predictive of adverse outcomes. J Am Acad Dermatol. 2018;79(5 ):853–859. doi:10.1016/j.jaad.2018.05.02229787841
   PubMed Web of Science ®Google Scholar
• Mendenhall WM, Indelicato DJ, Scarborough MT, et al. The management of adult soft tissue sarcomas. Am J Clin Oncol. 2009;32(4 ):436–442. doi:10.1097/COC.0b013e318173a54f19657238
   PubMed Web of Science ®Google Scholar
• Singer S, Demetri GD, Baldini EH, Fletcher CDM. Management of soft-tissue sarcomas: an overview and update. Lancet Oncol. 2000;1(2 ):75–85. doi:10.1016/S1470-2045(00)00016-411905672
   PubMedGoogle Scholar
• De Vita A, Recine F, Mercatali L, et al. Primary culture of undifferentiated pleomorphic sarcoma: molecular characterization and response to anticancer agents. Int J Mol Sci. 2017;18(12 ):2662. doi:10.3390/ijms18122662
   PubMed Web of Science ®Google Scholar
• Zheng B, Zhang S, Cai W, et al. Identification of novel fusion transcripts in undifferentiated pleomorphic sarcomas by transcriptome sequencing. Cancer Genomics Proteomics. 2019;16(5 ):399–408. doi:10.21873/cgp.2014431467233
   PubMed Web of Science ®Google Scholar